Navigation Links
Cell Therapeutics Completes Pixantrone NDA Submission and Requests Priority Review
Date:6/23/2009

Completed NDA submission could lead to marketing approval in Q4-2009

SEATTLE, June 24 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that it has completed the submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pixantrone to treat relapsed or refractory, aggressive non-Hodgkin's lymphoma (NHL). CTI requested priority review, which if granted could lead to an approval decision from the FDA in the fourth quarter of 2009. Pixantrone is currently available in Europe on a named-patient basis.

"This is a major milestone for CTI and is the cornerstone of a turnaround strategy for us in meeting our goals of becoming a profitable operating business," said James A. Bianco, M.D., Chief Executive Officer of CTI. "With more than 76,000 pages and 500,000 hyperlinks this submission represents the hard work of many CTI employees dedicated to making a difference in the lives of patients with cancer. This also represents a significant advance in the treatment of patients with relapsed/refractory aggressive NHL, a patient population which the FDA has acknowledged represents an unmet medical need."

About the PIX 301 EXTEND Trial

CTI's EXTEND (PIX 301) clinical trial (the "PIX 301 EXTEND trial") was a phase III single-agent trial of pixantrone for patients with relapsed or refractory, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The trial enrolled 140 patients and patients were randomized to receive either pixantrone or another single-agent drug currently used for the treatment of this patient population as selected by the physician.

CTI previously announced that its pivotal PIX 301 EXTEND trial had achieved its primary endpoint with patients randomized to treatment with pixantrone achieving a significantly higher rate of confirmed (CR) an
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Prime Therapeutics Receives TIPPS Certification
2. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
3. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
4. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
5. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
6. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
7. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
8. Prime Therapeutics Announces URAC Accreditation
9. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
10. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 06, 2015 The Gluten-Free Certification ... Association, is pleased to announce that Dufflet Pastries, ... has expanded their product line of gluten-free treats ... scrumptious and as satisfying as any of their ... and never contains hydrogenated fats or oils, artificial ...
(Date:3/6/2015)... (PRWEB) March 06, 2015 FCPX developers ... from Pixel Film Studios. , “Pro3rd Hue is a lower ... Austin, CEO of Pixel Film Studios. “Blurring the line between ... , Pro3rd Hue is a set of 30 customizable lower ... X. With Pro3rd Hue, FCPX users can complement any design ...
(Date:3/6/2015)... The producers of Health Briefs TV ... Washington and vicinity. This is a city which is full ... many outdoor activities. It is also a city where healthcare ... hospitals call the city home and provide care from the ... TV program will be broadcast on CBS KLEW-TV during the ...
(Date:3/6/2015)... Fluid Running® Owner, Jennifer Conroyd, an ... Fluid Running® method 3 years ago when ... She hit upon the trifecta of combining matched-bpm music, ... maximum-resistance, deep water running technique. She not only completed ... running workout that made the experience both enjoyable and ...
(Date:3/6/2015)... March 06, 2015 As the Mayo ... be discussed, Ford & Associates Nationwide Legal Services, A.P.C., ... 2015 filed lawsuit: Verduzco v. Daiichi Sankyo, Inc., Case ... California. , “In light of a recently filed ... Benicar to evaluate and explore the Mayo Clinic's Benicar ...
Breaking Medicine News(10 mins):Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 2Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 3Health News:Dufflet Pastries® Impressive Collection of Brownies, Cakes, Pies and Cakelets® Now Includes a Gluten-Free Line Certified By the GFCP. 4Health News:A New Plugin Entitled Pro3rd Hue was Released Today from Pixel Film Studios Exclusively for FCPX 2Health News:The Health Briefs TV Show to Air in Spokane, Washington 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 2Health News:Fluid Running®, the Revolutionary, No-Impact Running Workout, Expands Nationally with New Training Workshop 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 2Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 3Health News:Mayo Clinic's Benicar Case Study Findings Prompts Commentary from Ford & Associates Nationwide Legal Services in Wake of a Recently Filed Benicar Lawsuit 4
... biomedical sciences, they are playing a key role: living ... media populating incubators in laboratories around the world. But ... their culture dishes? Under the microscope, different cell lines ... these important research objects stop growing without apparent reason ...
... sunlight may be associated with the development of certain ... by researchers at the National Institute of Environmental Health ... "This study found that women who lived in ... developed an autoimmune muscle disease called myositis were more ...
... BEIJING, July 30 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies,Inc. ... China-based medical device,company that develops, manufactures and markets advanced ... independent internal,investigation and the expected reporting in late August ... year ended March 31, 2009 and the,quarter ended June ...
... are more apt to have joint replacement, study finds , ... protein strongly predict the risk of hip and knee joint ... shows. , The research involved 912 healthy people in Italy, ... knee or hip replacement between 1990 and 2005. Those with ...
... CAMBRIDGE, MA, July 30 /PRNewswire/ - rL Solutions, the ... today that it will be sponsoring the 2009 MITSS ... award at the MITSS 8th Annual Dinner and Fundraiser ... Copley Place Hotel. , MITSS established this award in ...
... , , SAN FRANCISCO, ... the city,s leading privately supported, non-profit animal welfare organization, has launched its ... Whether traveling out of town or staying home, out in the ... and easy reference: http://www.sfspca.org/promotions/summer-health-and-safety.html , ...
Cached Medicine News:Health News:New test for safer biomedical research results 2Health News:Sun exposure may trigger certain autoimmune diseases in women 2Health News:China Medical Technologies Announces the Substantial Completion of an Independent Internal Investigation and Expected Timing of Reporting of Unaudited Financial Results for the Quarter and Fiscal Year ended March 31, 2009 and the Quarter ended June 30, 20 2Health News:China Medical Technologies Announces the Substantial Completion of an Independent Internal Investigation and Expected Timing of Reporting of Unaudited Financial Results for the Quarter and Fiscal Year ended March 31, 2009 and the Quarter ended June 30, 20 3Health News:China Medical Technologies Announces the Substantial Completion of an Independent Internal Investigation and Expected Timing of Reporting of Unaudited Financial Results for the Quarter and Fiscal Year ended March 31, 2009 and the Quarter ended June 30, 20 4Health News:Biomarker Could Predict Severe Osteoarthritis 2Health News:rL Solutions to Sponsor 2009 MITSS HOPE Award 2Health News:The San Francisco SPCA Launches Online Guide for Summer Pet Health & Safety 2Health News:The San Francisco SPCA Launches Online Guide for Summer Pet Health & Safety 3
(Date:3/5/2015)... , March 5, 2015 Vermillion, ... solutions company focused on gynecologic disease, announced today ... results before the market open on Wednesday, March ... and webcast at 8:30am Eastern. Conference Call & ... at 8:30am Eastern/5:30am Pacific Domestic: , 800-753-9057International: , ...
(Date:3/5/2015)... TUSTIN, Calif. , March 5, 2015  BioPhotas, ... energy products that use patented photo-therapeutic technologies to treat ... has partnered with the Semper Fi Fund to provide ... members in need of pain management solutions.  ... reported, "The first Marine who used the Celluma at ...
(Date:3/5/2015)... N.J. , March 5, 2015  Medical ... which specializes in high complexity, state-of-the-art, automated DNA-based ... new Human Papillomavirus (HPV) testing which utilizes cutting ... Each year, approximately 12,000 women are ... United States . Genital Human Papillomaviruses (HPV) ...
Breaking Medicine Technology:Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 2BioPhotas, Inc. and the Semper Fi Fund Work Together to Provide Pain Relief to Injured Service Members 3Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 2Medical Diagnostic Laboratories, L.L.C., the Institute for Biomarker Research Announces New HPV Tests 3
... Chimerix, Inc., a biotechnology company developing orally-available antiviral ... the Board and Chief Scientific Officer, will participate on ... Therapeutics Conference on July 22nd, 2011, 10:30 am ET. ... Club in Washington, D.C. on July 20-22, 2011, and ...
... July 20, 2011 Concentric Medical, Inc., the global ... patients, today announced the launch of the expanded family ... the V 2.0 Soft and V 3.0 Soft, through ... Merci Retrievers® are now approved and reimbursed in Japan. ...
Cached Medicine Technology:Chimerix to Present at Infocast's 9th Annual Biodefense Vaccines & Therapeutics Conference 2Chimerix to Present at Infocast's 9th Annual Biodefense Vaccines & Therapeutics Conference 3Concentric Medical Launches Full Family of Merci Retrievers® in Japan 2Concentric Medical Launches Full Family of Merci Retrievers® in Japan 3
... The Z-View Aberrometer is the first ... needs of the dispensing Eye Care Practitioner. ... pending) the Z-View Aberrometer quickly and accurately ... well as sphere, cylinder and axis to ...
... American Industrial Laboratories, Inc. specializes in ... eyebank and laboratory specular microscopes, digital ... camera digital upgrade package. Our software ... image data correlation with rapid image ...
... user friendly computerized medical record system whose ... productivity of the practice as well as ... It provides clinical templates for commonly presenting ... also contains an exhaustive database to cover ...
... The Z-1 applanation tonometer is ... 3Z slit lamp or most "Zeiss" ... provides highly accurate intra-ocular pressure readings. ... the slit lamp and the prism ...
Medicine Products: